Creates a positive and motivating atmosphere.
Add your rating. It takes about 30 seconds.
Associate Professor Jason Lee is a leading cancer epigeneticist and Principal Research Fellow at the Frazer Institute, University of Queensland, where he also holds an Associate Professor position. He maintains adjunct appointments at the University of Queensland and Queensland University of Technology. Lee earned his BSc in Molecular Pathology from the University of New South Wales and his PhD from the University of Sydney, studying the in vivo role of growth factors in breast cancer. His postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, under a NIH program grant led by Professor Robert Weinberg at MIT's Whitehead Institute, focused on the transcriptional roles of cyclin D1 and estrogen receptor in breast cancer. As a senior research scientist at Seoul National University in Korea, he developed proficiency in epigenetic techniques including genome-wide RNA-seq and ChIP-seq analyses applied to transcriptional regulation and cancer epigenetics.
Lee's research investigates epigenetic regulation of tumor suppressors and oncogenes in aggressive cancers such as breast, ovarian, pancreatic, melanoma, and gynaecological malignancies. His work addresses immunotherapy resistance, histone modifying enzymes, circular RNAs as biomarkers and therapeutics, DNA damage responses, and spatial multi-omics for precision medicine. Key publications include 'G9a inhibition enhances checkpoint inhibitor blockade response in melanoma' (Clinical Cancer Research, 2021), 'Combined inhibition of G9a and EZH2 suppresses tumor growth via synergistic induction of IL24-mediated apoptosis' (Cancer Research, 2022), 'IL-10-producing Th1 cells possess a distinct molecular signature in malaria' (Journal of Clinical Investigation, 2023), 'Histone modifying enzymes in gynaecological cancers' (Cancers, 2021), and contributions to high-impact journals like Molecular Cell, PNAS, Nature Genetics, and Immunity. He holds two active patents and collaborates with pharmaceutical enterprises on novel therapeutics. Notable funding includes NHMRC Development Grant (2024-2027) for DMX8.1 in immunotherapy-refractory cancers, Ovarian Cancer Research Foundation grants for ovarian cancer detection, and Pankind Accelerator Grants for pancreatic cancer projects.
Explore University of Queensland's pioneering blood tests and biomarkers for early pancreatic cancer detection, alongside QIMR pilots and Australian advances boosting survival from 14%.
Photo by Precondo CA on Unsplash
Photo by Brecht Corbeel on Unsplash
Photo by Anne Nygård on Unsplash
Photo by Kelly Sikkema on Unsplash
Photo by Markus Winkler on Unsplash
Photo by Philip Strong on Unsplash
